AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37011013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 37011024 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU)
Number of subjects: 29
Study 37011024 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study 37011138 — intervention group
Group type: EXPERIMENTAL
Intervention: Larsucosterol (DUR-928) at doses of 30, 90, or 150 mg administered via intravenous infusion (1 or 2 infusions, 72 hours apart)
Number of subjects: 19
Study 37011138 — intervention group
Group type: EXPERIMENTAL
Intervention: Larsucosterol (30 or 90 mg)
Number of subjects: 19
Study 37011138 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) including corticosteroids
Number of subjects: 19
Study 37011138 — intervention group
Group type: EXPERIMENTAL
Intervention: Larsucosterol (DUR-928)
Number of subjects: 19
Study 37011153 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE app with phone coaching
Number of subjects: 41
Study 37011153 — intervention group
Group type: COMPARATOR
Intervention: Symptom-monitoring app with phone coaching
Number of subjects: 41
Study 37011163 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention; details on dosage and duration not available.
Number of subjects: 0
Study 37011163 — intervention group
Group type: EXPERIMENTAL
Intervention: Community participatory approaches; details on dosage and duration not available.
Number of subjects: 0
Study 37011163 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, inclusive research team led by a Black psychologist; details on dosage and duration not available.
Number of subjects: 0
Study 37011163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersectionality lens applied; details on dosage and duration not available.
Number of subjects: 0
Study 37011169 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention to prevent victimization of trans women and trans femmes; details on dosage and duration not available.
Number of subjects: 0
Study 37011387 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support tool
Number of subjects: 330
Study 37011387 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 330
Study 37011435 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation
Number of subjects: 0
Study 37011526 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat (≤300 mg/day twice daily, weight-adjusted)
Number of subjects: 20
Study 37011643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (7.5 million international units subcutaneously three times per week for up to 1 year)
Number of subjects: 67
Study 37011643 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R (six cycles every 3 weeks of intravenous dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)
Number of subjects: 67
Study 37011643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b after cross-over
Number of subjects: 67
Study 37011643 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R after cross-over
Number of subjects: 67
Study 37011650 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg orally once daily and cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or patient withdrawal.
Number of subjects: 52
Study 37011650 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan plus cabozantinib
Number of subjects: 52
Study 37011709 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (1 g tid for 8 weeks)
Number of subjects: 84
Study 37011709 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 84
Study 37011709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 37012012 — intervention group
Group type: EXPERIMENTAL
Intervention: Soprocare camera
Number of subjects: 0
Study 37012012 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer camera
Number of subjects: 0
Study 37012012 — intervention group
Group type: COMPARATOR
Intervention: Reference intraoral examination
Number of subjects: 0
Study 37012012 — intervention group
Group type: EXPERIMENTAL
Intervention: Soprocare camera and Consumer camera
Number of subjects: 0
Study 37012011 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk calculator for pulmonary progression in sarcoidosis patients
Number of subjects: 557
Study 37012011 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features measured during routine clinic visits
Number of subjects: 557
Study 37012011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function tests (forced vital capacity, forced expiratory volume in 1 s, diffusing capacity of the lung for carbon monoxide)
Number of subjects: 557
Study 37012011 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers measured during routine clinic visits
Number of subjects: 557
Study 37012015 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atorvastatin (40 mg daily)
Number of subjects: 0
Study 37012015 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 37012016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg/kg ilofotase alfa
Number of subjects: 1400
Study 37012016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study 37012023 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 72
Study 37012023 — intervention group
Group type: COMPARATOR
Intervention: Spinal instrumentation
Number of subjects: 72
Study 37012018 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based model for data extraction from unstructured EHRs
Number of subjects: 100000
Study 37012068 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma P-tau181 measurement
Number of subjects: 476
Study 37012068 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma P-tau181 added to logistic regression model
Number of subjects: 476
Study 37012068 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma P-tau181 tertiles
Number of subjects: 476
Study 37012068 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma P-tau181 ≤2.32 pg/mL
Number of subjects: 476
Study 37012068 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease, creatinine, and estimated glomerular filtration rate
Number of subjects: 476
Study 37012070 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 8151
Study 37012070 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 8151
Study 37012070 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal Forest model
Number of subjects: 8151
Study 37012180 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous chemoradiotherapy (CRT)
Number of subjects: 2297
Study 37012180 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous CRT
Number of subjects: 2297
Study 37012181 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Intravascular Lithotripsy (IVL)
Number of subjects: 70
Study 37012181 — intervention group
Group type: COMPARATOR
Intervention: Rotational Atherectomy (RA)
Number of subjects: 70
Study 37012173 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported functional capacity measures (METs, number of floors climbed, self-perceived fitness, level of physical activity)
Number of subjects: 15406
Study 37012173 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk factors (internal clinical risk model)
Number of subjects: 15406
Study 37012190 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Dialectical Behavior Therapy skills training
Number of subjects: 40
Study 37012306 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 240 mg orally, 1 tablet daily for 12 months (study group, n=50)
Number of subjects: 100
Study 37012306 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50) did not receive EGb 761 for the first 12 months
Number of subjects: 100
Study 37012306 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 240 mg orally, 1 tablet daily for an additional 12 months (after initial 12 months for control group)
Number of subjects: 100
Study 37012306 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological and neurological evaluations at v0, v2, and v4
Number of subjects: 100
Study 37012318 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-line endocrine therapy for gBRCAm carriers
Number of subjects: 170
Study 37012318 — intervention group
Group type: COMPARATOR
Intervention: Front-line chemotherapy
Number of subjects: 170
Study 37012343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low burden exercise protocol (two six-min walk tests)
Number of subjects: 51
Study 37012343 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 51
Study 37012461 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets (test formulation)
Number of subjects: 36
Study 37012461 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate tablets (reference formulation)
Number of subjects: 36
Study 37012498 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA guided approach
Number of subjects: 0
Study 37012498 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37012549 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Number of subjects: 32
Study 37012550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and cabozantinib
Number of subjects: 0
Study 37012551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib as a single agent in children (12 months to <18 years)
Number of subjects: 0
Study 37012551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib as a single agent in adults (≥18 years)
Number of subjects: 0
Study 37012551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib in combination with topotecan/cyclophosphamide in children (<18 years)
Number of subjects: 0
Study 37013442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids/long-acting beta-agonists (ICSs/LABAs)
Number of subjects: 4978
Study 37013442 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonists (LAMAs)
Number of subjects: 4978
Study 37013442 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA + LAMA
Number of subjects: 4978
Study 37013442 — intervention group
Group type: COMPARATOR
Intervention: Neither ICS nor long-acting bronchodilators
Number of subjects: 4978
Study 37013472 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TIVA
Number of subjects: 90
Study 37013472 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anaesthesia (SEVO)
Number of subjects: 90
Study 37013485 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital healthcare system rehabilitation
Number of subjects: 324
Study 37013485 — intervention group
Group type: COMPARATOR
Intervention: Conventional education-based rehabilitation
Number of subjects: 324
Study 37013499 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening for 30 minutes before surgery, during spinal anesthesia, and for 30 minutes after surgery
Number of subjects: 108
Study 37013499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music listening)
Number of subjects: 108
Study 37013586 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) for 6 months, three times per week
Number of subjects: 58
Study 37013586 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus education (CON)
Number of subjects: 58
Study 37013610 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR7280 (100 to 1000 mg BID)
Number of subjects: 70
Study 37013610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 37013654 — intervention group
Group type: EXPERIMENTAL
Intervention: High density spinal cord stimulation (SCS) for 6 months
Number of subjects: 18
Study 37013654 — intervention group
Group type: COMPARATOR
Intervention: No stimulation for 6 months (Control)
Number of subjects: 18
Study 37013654 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient related outcome measures
Number of subjects: 18
Study 37013654 — intervention group
Group type: EXPERIMENTAL
Intervention: Major cardiac adverse events
Number of subjects: 18
Study 37013654 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety endpoints
Number of subjects: 18
Study 37013676 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Number of subjects: 0
Study 37013954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (20 mg daily from days 1 to 21 of each 28-day cycle) + Rituximab (375 mg/m2 weekly, starting on cycle 1, day 1 until cycle 2, day 1) + Venetoclax (400 mg daily at maximum tolerated dose)
Number of subjects: 28
Study 37013954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide + Rituximab + Venetoclax
Number of subjects: 28
Study 37014057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (≥ 3%)
Number of subjects: 5205
Study 37014070 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge teaching intervention for older adults
Number of subjects: 30
Study 37014289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) sotalol loading dose
Number of subjects: 120
Study 37014289 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral (PO) loading
Number of subjects: 120
Study 37014289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) sotalol loading
Number of subjects: 120
Study 37014462 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask combined with HFNO
Number of subjects: 450
Study 37014462 — intervention group
Group type: COMPARATOR
Intervention: Facemask-alone
Number of subjects: 450
Study 37014505 — intervention group
Group type: EXPERIMENTAL
Intervention: MINST
Number of subjects: 20
Study 37014505 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 37014515 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Meter Backwalk Test (3MBWT)
Number of subjects: 55
Study 37014543 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG)
Number of subjects: 135
Study 37014543 — intervention group
Group type: COMPARATOR
Intervention: Conception within 18 months postoperative
Number of subjects: 135
Study 37014543 — intervention group
Group type: COMPARATOR
Intervention: Conception after 18 months postoperative
Number of subjects: 135
Study 37014580 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing E. coli carriers
Number of subjects: 255
Study 37014580 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing K. pneumoniae carriers
Number of subjects: 255
Study 37014580 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Sellimonas intestinalis
Number of subjects: 255
Study 37014580 — intervention group
Group type: EXPERIMENTAL
Intervention: Campylobacter ureolyticus, Campylobacter hominis, Clostridium cluster XI, Saccharomyces sp.
Number of subjects: 255
Study 37014668 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferred Immune Cell Activity (iICA) hot cluster tumors
Number of subjects: 279
Study 37014668 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferred Immune Cell Activity (iICA) warm cluster tumors
Number of subjects: 279
Study 37014668 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of tumor-infiltrating lymphocytes (TIL)
Number of subjects: 279
Study 37014668 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferred Immune Cell Activity (iICA) cluster
Number of subjects: 279
Study 37014668 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot or warm cluster tumors
Number of subjects: 279
Study 37014668 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell types inferred activity
Number of subjects: 279
Study 37014672 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy storing and returning prosthetic device
Number of subjects: 100
Study 37014672 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulating prosthetic device
Number of subjects: 100
Study 37014672 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered prosthetic device
Number of subjects: 100
Study 37014672 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 prosthetic devices concurrently
Number of subjects: 100
Study 37014672 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-body gait analysis (subset of 30 participants)
Number of subjects: 100
Study 37014673 — intervention group
Group type: EXPERIMENTAL
Intervention: IQOS-HTP
Number of subjects: 211
Study 37014673 — intervention group
Group type: COMPARATOR
Intervention: JustFog-EC
Number of subjects: 211
Study 37014940 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel motivational approach
Number of subjects: 0
Study 37014940 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37015033 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 37015033 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37015066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 99
Study 37015066 — intervention group
Group type: COMPARATOR
Intervention: Placebo stretching program
Number of subjects: 99
Study 37015066 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced vision dysfunction
Number of subjects: 99
Study 37015244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparsentan 400 mg once daily
Number of subjects: 404
Study 37015244 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 300 mg once daily
Number of subjects: 404
Study 37015291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic fascia-sparing robotic-assisted radical prostatectomy (PFS-RARP)
Number of subjects: 600
Study 37015291 — intervention group
Group type: COMPARATOR
Intervention: Conventional robotic-assisted prostatectomy (RARP)
Number of subjects: 600
Study 37015757 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Coefficient (RC) model
Number of subjects: 0
Study 37015757 — intervention group
Group type: COMPARATOR
Intervention: ANCOVA+LE
Number of subjects: 0
Study 37015757 — intervention group
Group type: COMPARATOR
Intervention: ANCOVA
Number of subjects: 0
Study 37015757 — intervention group
Group type: EXPERIMENTAL
Intervention: RC+observed (OBS)
Number of subjects: 0
Study 37015984 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 5041
Study 37015984 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 negative patients
Number of subjects: 5041
Study 37015984 — intervention group
Group type: COMPARATOR
Intervention: Patients without a COVID-19 test
Number of subjects: 5041
Study 37015984 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-positive status
Number of subjects: 5041
Study 37015996 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS spectacles for 6 years (Group 1)
Number of subjects: 90
Study 37015996 — intervention group
Group type: COMPARATOR
Intervention: DIMS spectacles for 6 years (Group 1) and DIMS spectacles for 2 years then switched to DIMS (Group 3)
Number of subjects: 90
Study 37015996 — intervention group
Group type: COMPARATOR
Intervention: Single vision spectacles (Group 2 and Group 4)
Number of subjects: 90
Study 37015996 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 37016126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W)
Number of subjects: 192
Study 37016126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W) with durvalumab 10 mg/kg intravenously Q2W
Number of subjects: 192
Study 37016126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleclumab in CRC expansion cohort
Number of subjects: 192
Study 37016126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleclumab in PDAC expansion cohort
Number of subjects: 192
Study 37016126 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleclumab in NSCLC expansion cohort
Number of subjects: 192
Study 37016181 — intervention group
Group type: COMPARATOR
Intervention: Work Productivity and Activity Impairment (WPAI) questionnaire
Number of subjects: 462
Study 37016181 — intervention group
Group type: COMPARATOR
Intervention: Migraine Specific Quality of Life Questionnaire version 2.1 (MSQv2.1)
Number of subjects: 462
Study 37016181 — intervention group
Group type: COMPARATOR
Intervention: Monthly migraine headache days
Number of subjects: 462
Study 37016181 — intervention group
Group type: COMPARATOR
Intervention: WPAI domain scores
Number of subjects: 462
Study 37016303 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, oxaliplatin, and S-1 (DOS regimen) followed by radical resection
Number of subjects: 73
Study 37016303 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (DOS regimen)
Number of subjects: 73
Study 37016303 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, oxaliplatin, and S-1 (DOS regimen) followed by radical resection after propensity score matching
Number of subjects: 73
Study 37016303 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (DOS regimen) after propensity score matching
Number of subjects: 73
Study 37016303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (resection and chemotherapy)
Number of subjects: 73
Study 37016309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium polystyrene sulfonate
Number of subjects: 80
Study 37016309 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 80
Study 37016309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Number of subjects: 80
Study 37016309 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (nonspecific laxative)
Number of subjects: 80
Study 37016309 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 37016326 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg oral) + Misoprostol (25 µg vaginal)
Number of subjects: 128
Study 37016326 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (25 µg vaginal) + Placebo
Number of subjects: 128
Study 37016326 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Misoprostol
Number of subjects: 128
Study 37016357 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor time (up to 2.3 hours per day)
Number of subjects: 3291